Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Gao, Jun ^a   Song, Jian ^a   Huang, Haojie ^a   Li, Zhaoshen ^a   Du, Yiqi ^a   Cao, Jia ^a   Li, Minghui ^b   Lv, Shunli ^a   Lin, Han ^a   Gong, Yanfang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Foundation Engineering Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; OSTEONECTIN; TOBACCO SMOKE; DNA;

ADULT; ALCOHOL CONSUMPTION; ANGIOGENESIS; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHRONIC PANCREATITIS; CLINICAL ARTICLE; DNA EXTRACTION; DNA SEQUENCE; EXTRACELLULAR MATRIX; FEMALE; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR CLONING; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; PROTEIN METHYLATION; RISK FACTOR; SEQUENCE ANALYSIS; TUMOR VOLUME; CHEMISTRY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; PANCREAS TUMOR; REGRESSION ANALYSIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CPG ISLANDS; DNA; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEONECTIN; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; REGRESSION ANALYSIS; SEQUENCE ANALYSIS, DNA;

EID: 77951931628     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-28     Document Type: Article

References (37)

1. Cancer statistics, 2004. A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thun, CA Cancer J Clin 2004 54 1 8 29 10.3322/canjclin.54.1.8 14974761
2. Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. KA Vanderveen SL Chen D Yin RD Cress RJ Bold, Cancer 2009 115 11 2420 2429 10.1002/cncr.24269 19301434
3. Antisense Smo under the control of the PTCH1 promoter delivered by an adenoviral vector inhibits the growth of human pancreatic cancer. J Gao Z Li Z Chen J Shao L Zhang G Xu Z Tu Y Gong, Gene Ther 2006 13 22 1587 1594 10.1038/sj.gt.3302816 16826192
4. Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer. W Wang J Gao XH Man ZS Li YF Gong, Oncol Rep 2009 21 6 1439 1447 19424621
5. The history of cancer epigenetics. AP Feinberg B Tycko, Nat Rev Cancer 2004 4 2 143 153 10.1038/nrc1279 14732866
6. Detection and interpretation of altered methylation patterns in cancer cells. T Ushijima, Nat Rev Cancer 2005 5 3 223 231 10.1038/nrc1571 15719030 (Pubitemid 40314953)
7. Genetic and epigenetic alterations of familial pancreatic cancers. K Brune SM Hong A Li S Yachida T Abe M Griffith D Yang N Omura J Eshleman M Canto R Schulick AP Klein RH Hruban C Iacobuzio-Donohue M Goggins, Cancer Epidemiol Biomarkers Prev 2008 17 12 3536 3542 10.1158/1055-9965.EPI-08-0630 19064568
8. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. AD Bradshaw EH Sage, J Clin Invest 2001 107 9 1049 1054 10.1172/JCI12939 11342565
9. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. RA Brekken EH Sage, Matrix Biol 2001 19 8 816 827 10.1016/S0945-053X(00)00133-5 11223341
10. Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. E Jendraschak EH Sage, Semin Cancer Biol 1996 7 3 139 146 10.1006/scbi.1996.0019 8773299
11. SPARC, a matricellular glycoprotein with important biological functions. Q Yan EH Sage, J Histochem Cytochem 1999 47 12 1495 1506 10567433
12. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. N Sato N Fukushima N Maehara H Matsubayashi J Koopmann GH Su RH Hruban M Goggins, Oncogene 2003 22 32 5021 5030 10.1038/sj.onc.1206807 12902985
13. Risk factors for pancreatic cancer. AB Lowenfels P Maisonneuve, J Cell Biochem 2005 95 4 649 656 10.1002/jcb.20461 15849724
14. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. D Oka S Yamashita T Tomioka Y Nakanishi H Kato M Kaminishi T Ushijima, Cancer 2009 115 15 3412 3426 10.1002/cncr.24394 19472401
15. Field effect in cancer-an update. H Chai RE Brown, Ann Clin Lab Sci 2009 39 4 331 337 19880759
16. Epidemiology of pancreatic cancer: an overview. S Raimondi P Maisonneuve AB Lowenfels, Nat Rev Gastroenterol Hepatol 2009 6 12 699 708 10.1038/nrgastro.2009.177 19806144
17. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. H Matsubayashi M Canto N Sato A Klein T Abe K Yamashita CJ Yeo A Kalloo R Hruban M Goggins, Cancer Res 2006 66 2 1208 1217 10.1158/0008-5472.CAN-05-2664 16424060
18. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. P Sova Q Feng G Geiss T Wood R Strauss V Rudolf A Lieber N Kiviat, Cancer Epidemiol Biomarkers Prev 2006 15 1 114 123 10.1158/1055-9965.EPI-05-0323 16434596
19. Aberrant methylation of SPARC in human lung cancers. M Suzuki C Hao T Takahashi H Shigematsu N Shivapurkar UG Sathyanarayana T Iizasa T Fujisawa K Hiroshima AF Gazdar, Br J Cancer 2005 92 5 942 948 10.1038/sj.bjc.6602376 15756262 (Pubitemid 40462643)
20. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. S Cheetham MJ Tang F Mesak H Kennecke D Owen IT Tai, Br J Cancer 2008 98 11 1810 1819 10.1038/sj.bjc.6604377 18458674
21. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. JF DiMartino NJ Lacayo M Varadi L Li C Saraiya Y Ravindranath R Yu BI Sikic SC Raimondi GV Dahl, Leukemia 2006 20 3 426 432 10.1038/sj.leu. 2404102 16424866
22. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. G Heller WM Schmidt B Ziegler S Holzer L Mullauer M Bilban CC Zielinski J Drach S Zochbauer-Muller, Cancer Res 2008 68 1 44 54 10.1158/0008-5472.CAN-07-2531 18172295
23. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. FJ Rodriguez-Jimenez T Caldes P Iniesta JA Vidart JL Garcia-Asenjo M Benito, Oncol Rep 2007 17 6 1301 1307 17487382
24. Aberrant promoter methylation of SPARC in ovarian cancer. MJ Socha N Said Y Dai J Kwong P Ramalingam V Trieu N Desai SC Mok K Motamed, Neoplasia 2009 11 2 126 135 19177197
25. Survey of differentially methylated promoters in prostate cancer cell lines. Y Wang Q Yu AH Cho G Rondeau J Welsh E Adamson D Mercola M McClelland, Neoplasia 2005 7 8 748 760 10.1593/neo.05289 16207477
26. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. JR Infante H Matsubayashi N Sato J Tonascia AP Klein TA Riall C Yeo C Iacobuzio-Donahue M Goggins, J Clin Oncol 2007 25 3 319 325 10.1200/JCO.2006.07.8824 17235047
27. Smoking and drinking can induce p15 methylation in the upper aerodigestive tract of healthy individuals and patients with head and neck squamous cell carcinoma. HW Chang GS Ling WI Wei AP Yuen, Cancer 2004 101 1 125 132 10.1002/cncr.20323 15221997
28. Detecting pathway-based gene-gene and gene-environment interactions in pancreatic cancer. EJ Duell PM Bracci JH Moore RD Burk KT Kelsey EA Holly, Cancer Epidemiol Biomarkers Prev 2008 17 6 1470 1479 10.1158/1055-9965.EPI-07- 2797 18559563
29. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. L Jiao J Zhu MM Hassan DB Evans JL Abbruzzese D Li, Pancreas 2007 34 1 55 62 10.1097/01.mpa.0000246665.68869.d4 17198183
30. Osteonectin influences growth and invasion of pancreatic cancer cells. A Guweidhi J Kleeff H Adwan NA Giese MN Wente T Giese MW Buchler MR Berger H Friess, Ann Surg 2005 242 2 224 234 10.1097/01.sla.0000171866.45848.68 16041213
31. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. OL Podhajcer LG Benedetti MR Girotti F Prada E Salvatierra AS Llera, Cancer Metastasis Rev 2008 27 4 691 705 10.1007/s10555-008-9146-7 18542844
32. Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. G Chen X Tian Z Liu S Zhou B Schmidt D Henne-Bruns M Bachem M Kornmann, Br J Cancer 2010 102 1 188 195 10.1038/sj.bjc.6605440 19920824
33. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. HG Linhart H Lin Y Yamada E Moran EJ Steine S Gokhale G Lo E Cantu M Ehrich T He A Meissner R Jaenisch, Genes Dev 2007 21 23 3110 3122 10.1101/gad.1594007 18056424
34. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. D Jia RZ Jurkowska X Zhang A Jeltsch X Cheng, Nature 2007 449 7159 248 251 10.1038/nature06146 17713477
35. CpG methylation plays a vital role in determining tissue- and cell-specific expression of the human cell-death-inducing DFF45-like effector A gene through the regulation of Sp1/Sp3 binding. D Li L Da H Tang T Li M Zhao, Nucleic Acids Res 2008 36 1 330 341 10.1093/nar/gkm1028 18033804
36. Maternal cocaine administration causes an epigenetic modification of protein kinase Cepsilon gene expression in fetal rat heart. H Zhang A Darwanto TA Linkhart LC Sowers L Zhang, Mol Pharmacol 2007 71 5 1319 1328 10.1124/mol.106.032011 17202284
37. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. DJ Wong SA Foster DA Galloway BJ Reid, Mol Cell Biol 1999 19 8 5642 5651 10409753